A new partnership deal struck between Q2 solutions, a clinical laboratory services organisation, and Thermo Fisher Scientific says it will speed up enrolment of patients in oncology clinical trials.
A joint venture of IQVIA and Quest Diagnostics, Q2 solutions will use Thermo Fisher’s next generation genomic sequencing platform: Ion Torrent Genexus system to deliver clinical trial lab results with unprecedented speed.
Thermo’s Ion Torrrent Genexus system improves the turnaround time and minimises human error for genome profiling, resulting in a better delivery.
With 70% of oncology drugs in development relying on genome profiling to uncover specific disease-causing mutations, Thermo Fisher said this is a significant advancement that may help people get the right therapy to the patient more quickly.
In a recent news release, Brian O’Dwyer, CEO of Q2 solutions said “clinical trial oncology patients require lab testing before they can receive potentially life-saving treatments, which makes lab testing turnaround time-critical”. He added that their “efforts in developing assays and tests to identify and target different aspects of disease are critical to drug discovery for pharma clients and adding the capabilities of the Ion Torrent Genexus System has the potential to drastically reduce our time to delivery clinical reports to trial sites, thereby enabling patient’s access to investigational drugs faster”.
